zur Navigation zum Inhalt



07/2016 Dear Colleagues,

Lung cancer mortality rates for both men and women have been declining in recent years. Early detection, refined understanding of tumour biology, and a variety of novel treatment options have made these advances possible. [...]

Mehr zum Thema

<< Seite 1 >>

Similar outcomes obtained with four adjuvant cisplatin-based chemotherapy regimens

07/2016 The phase III E1505 trial was designed to investigate the addition of bevacizumab to adjuvant chemotherapy in patients with early-stage, completely resected NSCLC. It was based on the rationale that the benefit of adjuvant cisplatin-based chemotherapy is modest in this population. [...]

PFS improvement due to local therapy in oligometastatic NSCLC

07/2016 Evidence suggests the existence of a ,limited metastatic’ NSCLC phenotype. However, the type of optimal treatment and the role of aggressive local therapy in these patients remain controversial. Gomez et al. presented the first prospective, randomised trial to address this question. [...]

Locally advanced NSCLC: oral vinorelbine shows better safety profile than etoposide

07/2016 The randomised, multicentre, open-label, phase II RENO trial was conducted with the objective of establishing a standard chemotherapy regimen in the setting of chemo-radiotherapy of locally advanced NSCLC. A total of 134 patients with inoperable stage III NSCLC received either oral vinorelbine plus cisplatin or etoposide plus cisplatin. [...]

ULTIMATE: chemotherapy plus bevacizumab beyond first line

07/2016 As chemotherapy in the second-line or third-line settings of NSCLC shows limited efficacy, the phase III, randomised ULTIMATE trial tested the combination of chemotherapy and bevacizumab in patients with advanced NSCLC of non-squamous histology, who had progressed after one or two lines of treatment. [...]

Mutational analysis: on the road to refined standards

07/2016 LCMC II

The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional consortium for the study of driver mutations of lung adenocarcinoma. The cooperating sites enable the identification of relatively large numbers of patients with uncommon and rare alterations, facilitate the analysis of their clinical characteristics, and lay the ground for targeted therapy trials. [...]

Exploring established and novel EGFR-directed agents

07/2016 PROs 13 % had further dose reductions to 20 mg. However, the rates of drug-related discontinuations due to AEs were similar across arms, which suggested that dose reductions effectively managed AEs. Indeed, dose adjustments led to decreases in the incidence and severity of drug-related AEs (FIGURE). [...]

Medizin heute

Aktuelle Printausgaben